Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: HRMY stock price vs MLI: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at MLI's multiple
Needs MLI P/E.
Implied fair value · at HRMY's multiple
Needs HRMY P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: HRMY FY 2025 (ended Dec 31, 2025) · MLI FY 2025 (ended Dec 27, 2025). Fiscal years are not aligned.
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 94% equity / 6% debt · EV / Revenue 2.13x · EV / EBITDA 7.28x
Capital structure 99% equity / 1% debt · EV / Revenue 3.07x · EV / EBITDA 11.85x
MLI carries the larger enterprise value at $12.81B against $1.85B; HRMY trades on the lower EV / Revenue multiple (2.13x vs 3.07x); HRMY on the lower EV / EBITDA (7.28x vs 11.85x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
HARMONY BIOSCIENCES HOLDINGS, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
MUELLER INDUSTRIES INC · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.19x
0.03x
Net debt / EBITDA
Leverage against operating earnings
-2.41x
-1.19x
Cash and equivalents
Liquid reserves on the balance sheet
$775.34M
$1.39B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Jazz Pharmaceuticals plc
HRMY vs JAZZ
SUPERNUS PHARMACEUTICALS, INC.
HRMY vs SUPN
Intra-Cellular Therapies, Inc.
HRMY vs ITCI
ACADIA PHARMACEUTICALS INC
HRMY vs ACAD
Vanda Pharmaceuticals Inc.
HRMY vs VNDA
LivaNova PLC
HRMY vs LIVN
NUCOR CORP
HRMY vs NUE
Howmet Aerospace Inc.
HRMY vs HWM
KAISER ALUMINUM CORP
HRMY vs KALU
COMMERCIAL METALS Co
HRMY vs CMC
$163.66M
$101.45M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
